Formulation: A solid
Formal Name: 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione, monohydrochloride, hydrate
Purity: ≥98%
Formula Markup: C11H7N5O4 • HCl [XH2O]
Formula Weight: 309,7
Shelf life (days): 1460
Notes: YM-90K is an AMPA receptor antagonist (Ki = 0.084 μM in a radioligand binding assay using rat brain membranes).{56153} It is selective for AMPA over kainate, NMDA-sensitive glutamate, and strychnine-insensitive glycine receptors (Kis = 2.2, >100, and 37 μM, respectively). Intrastriatal administration of YM-90K inhibits AMPA-induced decreases in choline acetyltransferase (ChAT) activity in rat striatum ex vivo in a dose-dependent manner. It inhibits audiogenic seizures in susceptible DBA/2 mice with a minimum effective dose of 3 mg/kg when administered intraperitoneally. Intravenous infusion of YM-90K (20 mg/kg per hour for 4 hours) reduces infarct size in a rat model of focal cerebral ischemia induced by thrombotic middle cerebral artery occlusion (MCAO) in rats.{56154}
English
Deutsch
